Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
By jointly finding a first-in-class atypical Protein Kinase C inhibitor preclinical candidate, Israel’s Teva and Britain’s Cancer Research Technology have successfully capped a four-year collaboration and are now branching out into the area of DNA damage response.
You may also be interested in...
STORM’s METTL3 Inhibitor Effective Against AML
Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.
Deal Watch: Oncology A Recurring Theme In Recent Spate Of Transactions
TetraLogic uses cash from its recent IPO to bring form to its oncology pipeline via the acquisition of Shape Pharmaceuticals. Also, GlaxoSmithKline becomes the latest big pharma to partner with MD Anderson Cancer Center’s Moon Shots program and Mersana will collaborate with Takeda on antibody-drug conjugates for cancer.
Cancer Research UK’s CRT: A Bridge Between Big Pharma And Academia
Britain’s Cancer Research Technology says the dire financing situation facing European biotechs has forced it to become a bridge builder between research-based Big Pharma and academia, an intermediary role that it expects to expand on as the search for new oncology drugs intensifies.